{
  "abstract": "The competing interest statement of this article by Robert Howard (BMJ 2024;386:q2044, doi:10.1136/bmj.q2044) has been amended to note that he was an unpaid member of the scientific board of Synaptogenix. The article has now been recategorised as an Opinion.",
  "authors": [
    {
      "affiliations": [],
      "name": "British Medical Journal Publishing Group"
    }
  ],
  "title": "Lecanemab’s benefits are too small and uncertain",
  "uid": "80595d7e-cfb5-54f1-8f32-a0170d8babd2"
}